Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 10 of 58, showing 10 Applications out of 576 total, starting on record 91, ending on 100

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

91.

ECCT/24/09/01   L9LS-PD
    Single-use antimalarial monoclonal antibodies for post-discharge malaria prevention in children with severe anaemia or severe malaria in Kenya: A multi-centre, parallel-group, two-arm randomised placebo-controlled non-inferiority trial (L9LS-pd)   
Principal Investigator(s)
1. Mary Iwaret Otiti
Site(s) in Kenya
1. Homa Bay County Teaching and Referral Hospital (Homa Bay county)
2. Siaya County Referral Hospital (Siaya county)
 
16-03-2025 View

92.

ECCT/24/08/06   KALUMA Study
    A randomized, open-label, multicenter study to compare efficacy, safety and tolerability of KLU156 with Coartem® in the treatment of uncomplicated Plasmodium falciparum malaria in adults and children ≥ 5 kg body weight followed by an Extension phase with repeated KLU156 treatment    
Principal Investigator(s)
1. Dr Patricia Odera Ojwang
2. Dr. Bernhards Ogutu
3. Dr.Bernhards Ogutu
Site(s) in Kenya
1. Site 1600: Kenya Medical Research Institute/Centre for Global Health Research Siaya (Siaya county)
2. Site 1601:Kombewa Clinical Research Centre (Kisumu county)
3. Ahero Clinical Trial Unit (Kisumu county)
 
26-01-2025 View

93.

ECCT/24/08/04   WHO A66045
    Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Machakos county hospital (Machakos county)
2. Pumwani maternity hospital (Nairobi City county)
3. Kiambu level 5 hospital (Kiambu county)
 
06-02-2025 View

94.

ECCT/24/08/03   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Mary Inziani Matilu
Site(s) in Kenya
1. KEMRI-Mtwapa Clinical Annex (Kilifi county)
2. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
3. Clinical Research Health Network (CREA-N) (Machakos county)
4. University of Nairobi Clinical Research Centre (Nairobi City county)
5. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
21-12-2024 View

95.

ECCT/24/08/02   S4V02
    Safety and immunogenicity of a second generation Shigella bioconjugate vaccine: a phase II randomized, controlled, and blinded study in 9-month-old infants   
Principal Investigator(s)
1. Richard Omore
Site(s) in Kenya
Siaya County Referral Hospital
 
07-01-2025 View

96.

ECCT/24/08/01   Evaluate clearance of HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Kevin Makori Gesimba
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Victoria Cancer Care and Research centre (Nyamira county)
 
16-10-2024 View

97.

ECCT/24/07/05   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Bernhards Ogutu
Site(s) in Kenya
1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county)
 
20-08-2024 View

98.

ECCT/24/07/04   AMC-114
    A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings       
Principal Investigator(s)
1. Dr. Naftali Busakhala
Site(s) in Kenya
Moi University Clinical Research Center
 
03-12-2024 View

99.

ECCT/24/07/03   RVF003 Trial
    Phase 2 trial to assess the immunogenicity and safety of the ChAdOx1 RVF vaccine against Rift Valley fever in adults in Kenya        
Principal Investigator(s)
1. George Warimwe
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme
 
06-01-2025 View

100.

ECCT/24/07/02   TMC278LAHTX4002
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county)
 
16-04-2025 View